Biotech Values

[microcapfun]

>>You have been mostly negative regarding Onxx, which is fine, but you have been most negative at the wrong times.<<

You have been unable to show that any of my statements involving Onyx were incorrect, so you attempt to negate them by labeling them "negative"? Dear me.

This discussion started simply because I said "One thing to keep in mind is that Carfilzomib has to be marketed to a quite different set of doctors compared to Nexavar - hematologists instead of oncologists, hepatologists, etc. Also Onyx plans to do its own marketing for Carfilzomib in Europe, which means ramping up from scratch there. My point is that there may not be much synergy associated with marketing these two very different drugs."

That was my entire post on ONXX from which you launched this strange 'micro is negative on ONXX' attack.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58125376


>>If you want to talk about profitability or lack there of, then breakdown expense and revenues. It is disingenuous of you to eliminate profits from the sale of Carfilzomib rights to Japan while including all the expenses accrued for the development of Carfilzomib.<<

Expenses and revenues are broken down right here:
http://www.sec.gov/Archives/edgar/data/1012140/000095012310100148/f56654e10vq.htm

You can see in that 10-Q that ONXX has lost $68m during the first 9 months of 2010, as I said before. That includes all GAAP Carfilzomib revenues and charges. I am not being "negative". That is a simple statement of fact.

Onyx also presents non-GAAP income in which they remove all one-time charges including milestones associated with the inlicensing of Carfilzomib and the rest of their pipeline, as well as non-cash charges such as stock comp and non-cash debt charges.
http://www.sec.gov/Archives/edgar/data/1012140/000095012310100112/f57249exv99w1.htm
That's O.K. But then they add back the *one-time* outlicensing fee that they received from Ono for selling Japan rights to Carfilzomib. It doesn't take a CPA to realize that this treatment is inconsistent and the company is also non-GAAP unprofitable at the present time. Talk to someone that you trust on accounting issues if you do not understand this.


>>Try being honest and analytical sometimes.<<

Huh?


>>Based on your posting record on the onxx board, you seem to be bitter about when you sold it.<<

??? I own close to $800,000 of ONXX at the present time, all of which is firmly in the green. If you think I am lying, bet me a few thousand dollars and I'll provide my account information to Dew.

>>You seem to want to eliminate future revenues from additional rights sales.<<

???

Clearly this discussion is a waste of time for both of us. I'll end it here.

micro